TGA approves use of Trikafta to treat cystic fibrosis F508del mutation in Australia – Vertex
Vertex Pharmaceuticals Incorporated announced that the Australian Therapeutic Goods Administration (TGA) has approved the use of Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for people with cystic fibrosis (CF) ages 12… read more.
